Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Columbia University

Merck Sharp + Dohme Corp.

Ono Pharmaceutical Co., Ltd.

Mercian Corporation and Eisai Co., Ltd.

Yasuhiro Funahashi

Yuji Yamamoto

Junji Matsui

Toru Haneda

Junichi Kamata

Taro Semba

Akihiko Tsuruoka

Keiko Takahashi

Toshiaki Wakabayashi

Naoko Hata

Norihiro Ueda

Tatsuo Watanabe

Tadashi Okabe

Kazumasa Nara

Takashi Owa

Shinichi Hamaoka

Hiroshi Obaishi

Yoichi Ozawa

Masayuki Matsukura

Tomohiro Matsushima

Noako Tsukahara

Tadashi Kadowaki

Kazuki Miyazaki

Yoshio Fukuda

Jan K Kitajewski

Carrie Shawber

Atsumi Yamaguchi

Katsuji Nakamura

Jason S Simon

Lucy Xu

Ken-ichi Nomoto

Sachi Suzuki

Fusayo Mimura

Yasuyuki Suzuki

Takuya Suzuki

Yoshio Watanabe

Kazuyuki Dobashi

Tomohiro Sameshima

Masanori Fujita

Kenichi Nomoto

Saori Miyano

Itaru Arimoto

Takayuki Nakagawa

Naoko Tsukahara

Naoto Ono

Yusuke Adachi

Takako Yoshiba

Taisuke Hoshi

Gursel Aktan

Vassiliki Karantza

RuiRong Yuan

Yusuke Narita

Kenji Matsui

Erhan Berrak

Taro Senba

Nobuaki Naruse

Rena Kawase

Pallavi Sachdev

Yukinori Minoshima

Michio Kanekiyo

Kazuhiko Yamada

Kentaro Takahashi

Ken-Ichi Nomoto

Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising sorafenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.

Biomarkers for a therapy comprising a sorafenib compound

A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.

Pharmaceutical composition for treating tumor

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.

Combination of a PD-1 antagonist and eribulin for treating cancer

Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.

Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds

An antitumor agent for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound or pharmaceutically acceptable salt thereof represented by Formula (II) exhibits an excellent antitumor effect compared to cases where these are individually used, and exhibits antitumor effects against various cancer types: wherein Ris azetidinyl and the like, Rto Ris a hydrogen atom or a halogen atom, Ris Ccycloalkyl and the like, Ris a hydrogen atom and the like, and Ris a halogen atom and the like.

Antitumor agent using compounds having kinase inhibitory effect in combination

This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.

Notch-based fusion proteins and uses thereof

A therapeutic agent for tumor for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound represented by Formula (II): wherein Ris Calkyl or Ccycloalkyl, Ris a hydrogen atom or Calkoxy, and Ris a hydrogen atom or a halogen atom, exhibits an excellent antitumor effect compared to cases where these are individually used.

Therapeutic agent for tumor

Compounds represented by the following general formula: wherein Ais an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xis &#x2014;O&#x2014;, &#x2014;S&#x2014;, etc.; Yis an optionally substituted Caryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tis a group represented by the following general formula: (wherein Eis a single bond or &#x2014;N(R)&#x2014;), Rand Reach independently represent a hydrogen atom, an optionally substituted Calkyl group, etc. and Zrepresents a Calkyl group, a Calicyclic hydrocarbon group, a Caryl group, etc.), salts thereof or hydrates of the foregoing.

Nitrogen-containing aromatic derivatives

Compounds represented by the following general formula: [wherein Ais an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xis &#x2014;O&#x2014;, &#x2014;S&#x2014;, etc.; Yis an optionally substituted Caryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tis a group represented by the following general formula: (wherein Eis a single bond or &#x2014;N(R)&#x2014;, Rand Reach independently represent a hydrogen atom, an optionally substituted Calkyl group, etc. and Zrepresents a Calkyl group, a Calicyclic hydrocarbon group, a Caryl group, etc.)],salts thereof or hydrates of the foregoing.

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, &#x2014;CH&#x2550;CH&#x2014; or &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mmeans an integer of 1 or 2); Rmeans hydrogen atom or a C1-C6 alkyl group; Z means a single bond or &#x2014;CO&#x2014;NH&#x2014;; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Integrin expression inhibitor

Compounds represented by the following general formula: [wherein Ais an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xis &#x2014;O&#x2014;, &#x2014;S&#x2014;, etc.; Yis an optionally substituted Caryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tis a group represented by the following general formula: (wherein Eis a single bond or &#x2014;N(R)&#x2014;, Rand Reach independently represent a hydrogen atom, an optionally substituted Calkyl group, etc. and Zrepresents a Calkyl group, a Calicyclic hydrocarbon group, a Caryl group, etc.)], salts thereof or hydrates of the foregoing.

Growing community of inventors

Tsukuba, Japan

Yasuhiro Funahashi